Disclosures

Al Benson III MD, FACP, FASCO

Professor, Medicine, Hematology Oncology Division; Feinberg School of Medicine; Director for Cooperative Groups at the Robert H. Lurie Comprehensive Cancer Center

Reported no conflicts of interest

Jennifer R. Brown, MD, PhD

Associate Professor of Medicine, Dana-Farber Cancer Institute

Received clinical research support/data safety monitoring board from Acerta Pharma, BeiGene, Eli Lilly and Company

Served on scientific advisory board or as a consultant or expert witness for AbbVie, Acerta Pharma, BeiGene, Eli Lilly and Company, MEI Pharma, and Pfizer

David S. Ettinger, MD, FACP, FCCP

Alex Grass Professor of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

Served on scientific advisory board or as a consultant or expert witness for Alkemes, AstraZeneca Pharmaceuticals, BeyondSpring Pharmaceuticals, Bristol-Myers Squibb, and Guardant Health

William J. Gradishar, MD

Director, Clinical Network; Chief, Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago

Received clinical research support/data safety monitoring board from Genentech and Seattle Genetics

Served on scientific advisory board or as a consultant or expert witness for Abbott Laboratories, AstraZeneca Pharmaceuticals, Genentech, Merck & Co, and Pfizer

Robert I Haddad, MD

Chief, Division of Head and Neck Oncology and Institute Physician, Dana-Farber Cancer Institute; Professor of Medicine, Harvard Medical School

Received clinical research support/data safety monitoring board from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Genentech, Kura Oncology, Merck & Co, and Pfizer

Served on scientific advisory board or as a consultant or expert witness for AstraZeneca Pharmaceuticals, Aveo Pharmaceuticals, Bristol-Myers Squibb, Celgene, Eisai, Genentech, GlaxoSmithKline, Kura Oncology, and Merck & Co

Gabriela Hobbs, MD

Clinical Director, Leukemia Service at Massachusetts General Hospital

Served on scientific advisory board or as a consultant or expert witness for Agios, Celgene Corporation, Incyte Corporation, and Jazz Pharmaceuticals.

Prashant Kapoor, MD

Assistant Professor of Medicine and Oncology (Division of Hematology), Mayo Clinic, Rochester, Minnesota

Served on scientific advisory board or as a consultant or expert witness for Argos Therapeutics, Bristol-Myers Squibb, Celgene, Jazz Pharmaceuticals, and Novartis.

Has received personal compensation from Pharmacyclics, Cellectar and Karyopharm for serving on scientific advisory board or as a consultant.

Involved in the development of Mayo Clinic mSMART guidelines.

Shaji K. Kumar, MD

Professor of Medicine, Mayo Clinic, Rochester, Minnesota

Received clinical research support/data safety monitoring board from AbbVie, Allogene, Bristol-Myers Squibb, Carsgen, Celgene, GlaxoSmithKline, MedImmune, Oncogene, Roche Laboratories, Takeda Pharmaceuticals North America, and Tenebio

Served on scientific advisory board or as a consultant or expert witness for AbbVie, Celgene, Cellectar, Genecentrix, Oncopeptides, Roche Laboratories, and Takeda Pharmaceuticals North America

Karl D. Lewis, MD

Associate Professor, Division of Medical Oncology, University of Colorado Denver School of Medicine

Received clinical research support from or served on data safety monitoring board for Array, Bristol-Myers Squibb, Incyte, Iovance, Kartos, Merck & Co, Nektar Therapeutics, Neon, Oncosec, Regeneron Pharmaceuticals, and Roche Laboratories

Served on scientific advisory board or as a consultant or expert witness for Genentech, Merck & Co, and Regeneron Pharmaceuticals

Michael J. Mauro, MD

Leader, Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York

Received clinical research support from or served on data safety monitoring board as principal investigator for Novartis Pharmaceuticals Corporation.

Served on scientific advisory board or as a consultant or expert witness for Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation, Takeda Pharmaceuticals North America, Inc., and Pfizer, Inc.

Rebecca Olin, MD, MS

Associate Professor, Department of Medicine (Hematology/Oncology), UCSF

Received clinical research support from or served on data safety monitoring board for Astellas Pharma US, AstraZeneca Pharmaceuticals, Daiichi-Sankyo Co, Genentech, MedImmune, Mirati, Novartis, Pfizer, and Spectrum Pharmaceuticals

Served on scientific advisory board or as a consultant or expert witness for Amgen, Genentech, and Revolution Medicine

Sandy Srinivas, MD

Professor of Medicine, Stanford University Medical Center

Received clinical research support from or served on a data safety monitoring board for AstraZeneca Pharmaceuticals, Bayer HealthCare, Bristol-Myers Squibb, Clovis Oncology, Eisai, Exelixis, Genentech, Merck &  Co, Pfizer, Seattle Genetics, and Tracon Pharmaceuticals

Served on scientific advisory board or as a consultant or expert witness for Bayer HealthCare, Eisai, Genentech, Janssen Pharmaceutica Products, and Merck & Co

Theresa L. Werner, MD

Medical Director, Clinical Trials Office; Associate Professor of Medicine, Oncology Division, Huntsman Cancer Institute, University of Utah, Salt Lake City

Reported no conflicts of interest

Medical Writers:

The following medical writers reported no conflicts of interest.

Sarah Campen, PharmD; Cordi Craig; Joseph Cupolo; Celeste L. Dixon;  Dana A. Elya, MS, RD, CDN; Joseph Fanelli; Julia Fiederlein; Melissa E. Fryman, MS; Lauren Harrison, MS; Kelly M. Hennessey, PhD; Nahae Kim, MPH; Susan London; Margie Miller; Anna Nowogrodzki; Hillary Ojeda; Susan Reckling; Kayci Reyer; Max J. Rosenthal; Jocelyn Solis-Moreira, MS; Melissa Steele-Ogus; Joshua Swore and Sara Tewksbury